Biotechnology News and Research

RSS

Domainex wins 2010 Genesis Life Science Innovation and Enterprise Programme Of The Year Award

Domainex Ltd, the leading UK-based drug discovery CRO, has won the 2010 Genesis Life Science Innovation and Enterprise Programme Of The Year Award. This Award was made in recognition of Domainex's proactive work on promoting academic-industry collaborations, and was adjudicated by leading representatives of the biotechnology and pharmaceutical industries.

From Domainex 15 Dec 2010

CTT, Bayer sign Research and License Option Agreement

Cancer Targeted Technology (CTT), a Seattle-based biotechnology firm focusing on small molecule cancer enzyme inhibitors for the generation of novel diagnostics and therapeutics, today announced that it has signed a Research and License Option Agreement with Bayer Pharma AG, Germany. Under the agreement, CTT will work with Bayer to optimize a novel PET imaging agent based on its unique inhibitor scaffold that recognizes a validated cancer enzyme biomarker.

15 Dec 2010

Court dismisses Illumina's patent infringement lawsuits against Affymetrix

Affymetrix, Inc. today announced that the U.S. District Court for the Western District of Wisconsin (the "Court") has granted the company's motion for summary judgment that Affymetrix does not infringe the patents held by Illumina, Inc., and has directed that the patent infringement lawsuits brought against the company by Illumina regarding U.S. Patent Nos. 7,510,841 and 7,612,020 be dismissed and the cases closed.

From Illumina, Inc. 15 Dec 2010

Echo acoustic liquid handler improves discovery of potential therapeutics

When the revolutionary Echo® acoustic liquid handler is used in the process of discovering potential therapeutics, important drug candidates are identified that are missed using traditional liquid handlers. In a recently issued patent, the global pharmaceutical company AstraZeneca describes the discovery of a novel set of potential cancer therapeutics that was found only when the Echo system was used. Other major pharmaceutical companies have also reported that the Echo liquid handler was a critical platform in discovering drug candidates.

15 Dec 2010

Positive results from Creabilis CT327 Phase IIa study in atopic dermatitis

Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, announced positive results in the Phase IIa study of its lead product CT327 in atopic dermatitis.

15 Dec 2010

New skincare product with cellular activators

Scientists in Iceland have developed a revolutionary skincare product after more than a decade of extensive research in plant biotechnology. The skin-rejuvenating phenomenon is called BIOEFFECT(TM) EGF Serum. Made by Sif Cosmetics, it is the world's first skincare product to contain cellular activators made in plants. Six months after its launch in Iceland, the serum is already being used by over 20% of Icelandic women.

15 Dec 2010

Researchers develop synthetic circuits to detect changes in state of health

Using yeast cells, a group of researchers at the University of Gothenburg, Sweden, has taken a groundbreaking step towards being able to build complex systems in the future where the body's own cells help to keep us healthy.

15 Dec 2010

DSM licenses c-LEcta's alcohol dehydrogenases for enzyme screening programs

DSM Pharmaceutical Products, the custom manufacturing organization of Royal DSM NV, today announces a license agreement with c-LEcta GmbH for proprietary screening technology.

15 Dec 2010

Cell Biosciences receives US Patent for NanoPro assay technology

Cell Biosciences, Inc. today announced the issuance of Patent No. 7,846,676 for "Methods and Devices for Analyte Detection" by the United States Patent and Trademark Office.

15 Dec 2010

Myotec, Hybrid merge to form PsiOxus Therapeutics

Myotec Therapeutics, Ltd. and Hybrid BioSystems, Ltd. today announced their merger to form PsiOxus Therapeutics, Ltd. (PsiOxus), a new, development stage biotechnology company using non-traditional approaches to novel therapeutics for cancer and wasting diseases. PsiOxus, which will be led by CEO Dr. John Beadle, boasts a combined pipeline of phase I and II clinical stage assets.

15 Dec 2010

CRI introduces new model of philanthropic investment to improve cancer patient care

Cancer Research Institute, Inc. (CRI), a U.S. nonprofit organization established in 1953 to advance the science of tumor immunology and foster the discovery of new cancer immunotherapies, announced today the launch of the Cancer Vaccine Acceleration Fund (CVAF), a new model of philanthropic investment and academic-industry collaboration established in partnership with the Ludwig Institute for Cancer Research Ltd (LICR) to speed the clinical development of therapeutic cancer vaccines and other immune system-based therapies.

15 Dec 2010

CGEN-15001 administration shows dramatic therapeutic potential in CIA animal model

Compugen Ltd. announced today that administration of CGEN-15001 in an animal model of rheumatoid arthritis dramatically ameliorates the clinical symptoms of the disease.

15 Dec 2010

DARPA awards Pulmatrix $5.7 million grant to advance iCALM therapies

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced that it has been awarded a grant for $5.7 million from the Defense Advanced Research Projects Agency (DARPA), a component of the Department of Defense (DOD), focused on identifying and advancing novel technologies to support defense of our nation's soldiers and civilian population.

14 Dec 2010

Talecris evaluates response to $37M jury verdict in favor of Plasma Centers of America

Talecris Biotherapeutics Holdings Inc. announced today that a jury in the General Court of Justice, Superior Court Division, Wake County, North Carolina, rendered a verdict on December 13, 2010 in the amount of $37 million in favor of Plasma Centers of America, LLC, against its subsidiary, Talecris Plasma Resources, Inc., in a breach of contract claim.

14 Dec 2010

Life Technologies announces launch of Ion Personal Genome Machine sequencer

Life Technologies Corporation, a provider of innovative life science solutions, today announced that it has launched its Ion Personal Genome Machine (PGM™) sequencer, the first product to use semiconductor sequencing technology. The sequencer is shipping to select sites in North America, Europe and Asia Pacific.

14 Dec 2010

ProJect Pharmaceutics opens laboratory facilities in Martinsried, Munich

ProJect Pharmaceutics started business operations and opened its laboratory facilities in the Biotech-cluster in Martinsried, near Munich. ProJect Pharmaceutics transforms proteins, peptides and delicate small molecules into pioneering drugs.

14 Dec 2010

Novel labeling technique helps researchers to explore DNA chemical modification

Researchers at Emory University School of Medicine and the University of Chicago have developed a method for labeling and mapping a "sixth nucleotide," whose biological role scientists are only beginning to explore.

14 Dec 2010

Capstone presents AZX100 Phase 2a trial results for keloid and trocar site scarring

Capstone Therapeutics announced today twelve-month results from its two AZX100 Phase 2a pilot clinical trials in keloid scarring and seven-month interim results of its ongoing AZX100 Phase 2a pilot clinical trial in surgical (trocar site) scarring.

14 Dec 2010

Cedarlane to distribute TGR's new ELISA-One technology assay reagents in Canada and the US

TGR BioSciences, a leading global provider of advanced cell based assay technologies in the fields of cancer, kinase and GPCR research, is extremely pleased to announce a distribution partnership with Cedarlane Laboratories of Burlington, ON, Canada, a leading supplier of Life Science research reagents in North America.

13 Dec 2010

New positive data on Generex Oral-lyn published in Diabetes, Obesity and Metabolism

Generex Biotechnology Corporation announced today that the peer-reviewed scientific journal Diabetes, Obesity and Metabolism has published new positive data in respect of Generex Oral-lyn™, the Company's proprietary buccal insulin spray product.

13 Dec 2010